Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Nicoletta Ziglioli"'
Autor:
Daniele Generali, Andrea Rocca, Carla Strina, Manuela Milani, Enrico Fiorino, Valeria Cervoni, Carlo Azzini, Antonella Saracino, Ingnazio Ciliberto, Nicoletta Ziglioli, Marzia Alberio, Fabiola Giudici, Martina Dester, Oriana Ciani, Giulia Fornaro, Sergio Aguggini, Christa Dreezen, Darina Pronin, Stefanie Ende
Publikováno v:
Heliyon, Vol 10, Iss 21, Pp e39485- (2024)
Purpose: The aim of this study was to assess the prognostic performance of the 70-gene signature, MammaPrint, in an Italian single-center prospective cohort of early-stage intermediate-risk breast cancer (BC) patients. Methods: A total of 195 eligibl
Externí odkaz:
https://doaj.org/article/2786ca856aa34c789634138ba4c8b901
Autor:
Francesco Schettini, Maria Valeria De Bonis, Carla Strina, Manuela Milani, Nicoletta Ziglioli, Sergio Aguggini, Ignazio Ciliberto, Carlo Azzini, Giuseppina Barbieri, Valeria Cervoni, Maria Rosa Cappelletti, Giuseppina Ferrero, Marco Ungari, Mariavittoria Locci, Ida Paris, Giovanni Scambia, Gianpaolo Ruocco, Daniele Generali
Publikováno v:
Scientific Reports, Vol 13, Iss 1, Pp 1-11 (2023)
Abstract Mathematical models based on partial differential equations (PDEs) can be exploited to handle clinical data with space/time dimensions, e.g. tumor growth challenged by neoadjuvant therapy. A model based on simplified assessment of tumor mali
Externí odkaz:
https://doaj.org/article/8ab5d27f2a0c432f915f67cda4c6e7d3
Autor:
Francesco Schettini, Silvia Paola Corona, Fabiola Giudici, Carla Strina, Marianna Sirico, Ottavia Bernocchi, Manuela Milani, Nicoletta Ziglioli, Sergio Aguggini, Carlo Azzini, Giuseppina Barbieri, Valeria Cervoni, Maria Rosa Cappelletti, Alfredo Molteni, Maria Chiara Lazzari, Giuseppina Ferrero, Marco Ungari, Elena Marasco, Alice Bruson, Luciano Xumerle, Elisa Zago, Davide Cerra, Marco Loddo, Gareth H. Williams, Ida Paris, Giovanni Scambia, Daniele Generali
Publikováno v:
Frontiers in Oncology, Vol 11 (2021)
IntroductionOlaparib is effective in metastatic triple negative breast cancer (TNBC) carrying germline mutations in DNA damage repair (DDR) genes BRCA1/2 (gBRCA-mut). The OLTRE window-of-opportunity trial preliminarily investigated potential patholog
Externí odkaz:
https://doaj.org/article/63788280c6b64a3b8d56a89d2a4c7a48
Autor:
Ottavia Bernocchi, Marianna Sirico, Silvia Paola Corona, Carla Strina, Manuela Milani, Maria Rosa Cappelletti, Giuseppina Ferrero, Nicoletta Ziglioli, Valeria Cervoni, Andrea Macchiavelli, Giandomenico Roviello, Daniele Generali
Publikováno v:
Pharmaceuticals, Vol 14, Iss 2, p 159 (2021)
Background: Precision medicine is based on molecular and genotypic patient characterization to define specific target treatment. BRAF mutation is an oncogenic driver, and the Cancer Genome Atlas has identified BRAF mutations in different cancer types
Externí odkaz:
https://doaj.org/article/2267f4227c6842339e1e8d18b2ce1936
Autor:
Giandomenico Roviello, Daniele Generali, Silvia Paola Corona, Nicoletta Ziglioli, Valeria Cervoni, Marianna Sirico, Maria Rosa Cappelletti, Carla Strina, Giuseppina Ferrero, Ottavia Bernocchi, Andrea Macchiavelli, Manuela Milani
Publikováno v:
Pharmaceuticals
Pharmaceuticals, Vol 14, Iss 159, p 159 (2021)
Pharmaceuticals, Vol 14, Iss 159, p 159 (2021)
Background: Precision medicine is based on molecular and genotypic patient characterization to define specific target treatment. BRAF mutation is an oncogenic driver, and the Cancer Genome Atlas has identified BRAF mutations in different cancer types
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8bbb7a40d57ac410612170012aa5c813
http://europepmc.org/articles/PMC7920250
http://europepmc.org/articles/PMC7920250
Autor:
Federico Nichetti, Carla Strina, Marianna Sirico, Giulia Bianchi, Maria Rosa Cappelletti, Silvia P. Corona, Valeria Cervoni, Manuela Milani, Filippo de Braud, Navid Sobhani, Giuseppina Barbieri, Daniele Generali, Martina Dester, Fabiola Giudici, Claudio Vernieri, Ottavia Bernocchi, Nicoletta Ziglioli
Publikováno v:
Cancers
Cancers, Vol 12, Iss 3314, p 3314 (2020)
Volume 12
Issue 11
Cancers, Vol 12, Iss 3314, p 3314 (2020)
Volume 12
Issue 11
Background: The mTORC1 inhibitor everolimus has been approved in combination with the aromatase inhibitor exemestane for the treatment of hormone receptor-positive (HR+) human epidermal growth factor receptor 2-negative (HER2&minus
) metastatic
) metastatic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::102fd82d9e6e9435f32d6ba828b990fd
http://hdl.handle.net/11577/3401262
http://hdl.handle.net/11577/3401262
Autor:
Giuseppina Barbieri, Martina Dester, Marianna Sirico, Eva Ciruelos, Manuela Milani, Fabiola Giudici, Daniele Generali, Silvia Paola Corona, Valeria Cervoni, Carla Strina, Guy Jerusalem, Filippo Montemurro, Nicoletta Ziglioli, Ottavia Bernocchi
Publikováno v:
Oncotarget
Introduction Reliable biomarkers of response to mTOR inhibition are yet to be identified. As mTOR is heavily implicated in cell-metabolism, we investigated the relation between BMI variation and outcomes in metastatic breast cancer (mBC) patients tre
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5e654b37ae4d5d0403509e589ec02fe0
http://hdl.handle.net/11368/2993058
http://hdl.handle.net/11368/2993058
Autor:
Silvia P. Corona, Fabiola Giudici, Guy Jerusalem, Eva Ciruelos, Carla Strina, Marianna Sirico, Ottavia Bernocchi, Manuela Milani, Martina Dester, Nicoletta Ziglioli, Giuseppina Barbieri, Valeria Cervoni, Filippo Montemurro, Daniele Generali
Publikováno v:
Oncotarget. 13:1307-1307
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2663e227ddb1096d691420cbb7f04614
https://doi.org/10.18632/oncotarget.28317
https://doi.org/10.18632/oncotarget.28317